TNFRSF17 and AL amyloidosis: Recently, the FDA has approved a CAR-T cell immunotherapy for multiple myeloma; the first-in-class B-cell maturation antigen (BCMA)-targeted CAR-T cell therapy received the agency’s approval on March 26, 2021, to treat adults with relapsed/refractory multiple myeloma (9, 10).